Last updated: July 22, 2026
Salix Pharmaceuticals, Inc. v. Norwich Pharmaceuticals, Inc., No. 1:24-cv-07140, is a patent-infringement litigation matter filed in 2024 in the District of New Jersey. The procedural posture, asserted patents, claims, and relief sought are not specified in the provided input, so an accurate litigation merits summary and patent strength analysis cannot be produced from the available information.
What is Salix v. Norwich Pharmaceuticals (1:24-cv-07140) about?
A case caption and docket number identify the matter, but do not, by themselves, provide the technical and legal substance needed for a litigation summary. A correct and complete litigation analysis requires at minimum: the asserted patent numbers, the accused product(s), the relevant FDA submission type (e.g., ANDA Paragraph IV), and the specific infringement theories.
What court and procedural posture applies to 1:24-cv-07140?
- Case number: 1:24-cv-07140
- Parties: Salix Pharmaceuticals, Inc. (plaintiff) v. Norwich Pharmaceuticals, Inc. (defendant)
- Court: District of New Jersey (as indicated by the numbering scheme)
- Filing year: 2024
No additional docket-stage facts (complaint date, TRO/VSO motions, amended pleadings, claim construction schedule, summary judgment posture, settlement, or dismissal) are included in the input.
Which patents did Salix assert against Norwich in 1:24-cv-07140?
The asserted patent estate is not provided. Without the asserted patent list, any attempt to summarize infringement, design-around pathways, or invalidity positions would be speculative.
How do courts typically frame Salix vs. generic filers (ANDA Paragraph IV)?
In Salix-led Hatch-Waxman suits, plaintiffs typically plead:
- Infringement of one or more Orange-Book-listed patents tied to the reference product or formulation/method-of-use;
- Patent invalidity or non-infringement responses by defendants;
- FDA approval timing and 21 U.S.C. § 355(j) stay effects when Paragraph IV notice is involved.
The input does not establish that this case follows that pattern, nor which patents are involved.
Is there a Paragraph IV ANDA challenge in Salix v. Norwich?
The input does not include the FDA pathway, FDA submission identifier (ANDA/BLA/NDA), or Paragraph IV notice details. Those details drive:
- Whether a statutory 30-month stay applied;
- Whether a settlement occurred under 21 U.S.C. § 355(j)(5)(B);
- Whether a final judgment affects automatic triggers for generic launch risk.
No such facts are provided.
What is the Orange Book status of the patents at issue in 1:24-cv-07140?
Orange Book listings require:
- Product name and NDA/ANDA references;
- Patent numbers listed for that reference product;
- Expiration dates and exclusivity codes.
None of those inputs are present, so Orange Book status cannot be stated.
How strong is the patent estate for Salix’s asserted claims in this case?
Patent strength analysis requires:
- Claim scope (independent and dependent claims);
- Priority and prosecution history context;
- Known claim construction outcomes;
- Defendant’s non-infringement arguments tied to product composition/dosage form/release profile;
- Prior art references invoked and the court’s posture on invalidity.
No asserted claims, claim language, or invalidity contentions are supplied.
What did Norwich argue for non-infringement or invalidity?
Defenses are not provided. A litigation analysis that is decision-grade depends on:
- Whether Norwich challenged anticipation/obviousness;
- Whether Norwich argued lack of written description/enablement;
- Whether Norwich targeted specific limitations (e.g., coating, release kinetics, active composition, polymorph);
- Whether Norwich argued non-infringement based on formulation differences.
No contentions are included.
What did the court decide so far in 1:24-cv-07140?
A credible litigation status requires docket events such as:
- Motions to dismiss outcomes (Rule 12(b)(6));
- Claim construction orders (Markman);
- Daubert rulings;
- Summary judgment or partial summary judgment;
- Trial dates and evidentiary rulings;
- Settlement and dismissal orders.
No docket decisions are included.
Were there settlement terms, consent judgments, or stipulations in this case?
Settlement timing and terms are typically reflected by:
- Dismissal-with-prejudice dates;
- Consent judgments detailing launch/labeling dates;
- Confidential settlement agreements not reflected in public docket entries, though docket often shows the procedural end state.
The input contains no settlement information.
What generic launch risk exists for Norwich (and when)?
Launch risk depends on:
- Final patent validity/infringement outcomes;
- The scope of any injunctions;
- Any court-ordered or settlement-based launch dates;
- Regulatory readiness (manufacturing, bioequivalence, labeling);
- Any exclusivity barriers beyond patents.
None of those facts are provided.
How does this litigation compare with other Salix patent cases against generic filers?
Comparative analysis requires:
- Other case numbers, asserted patents, and outcomes;
- Similar product/formulation or therapeutic area overlaps;
- Repeated invalidity arguments and recurring claim construction patterns.
No related-case details are given.
Key Takeaways
- The input identifies a single matter, Salix Pharmaceuticals, Inc. v. Norwich Pharmaceuticals, Inc., No. 1:24-cv-07140, but provides no asserted-patent, product, FDA, or docket-outcome facts.
- Without those elements, a complete and accurate litigation summary and patent strength analysis cannot be produced.
FAQs
- What are the asserted patents in Salix Pharmaceuticals v. Norwich Pharmaceuticals (1:24-cv-07140)?
- Does 1:24-cv-07140 involve an ANDA Paragraph IV notice and a 30-month stay?
- What injunction or remedy does Salix seek in this case?
- What is the current procedural stage of 1:24-cv-07140 (motions, Markman, trial)?
- Did the parties settle, and if so, what launch date or labeling restriction applies?
References
- (No citable sources were provided in the prompt beyond the docket number and caption.)
